Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XOMA Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
XOMA Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XOMA Corp, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 12
XOMA to Acquire Assets from Enumeral Biomedical for USD1.6 Million 13
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 14
Private Equity 15
XOMA Sells Royalty Rights to HealthCare Royalty Partners 15
Partnerships 16
Domain Therapeutics Enters into Agreement with Xoma 16
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 17
Licensing Agreements 18
Rezolute Enters into Licensing Agreement with XOMA 18
Tizona Therapeutics Enters into Licensing Agreement with XOMA 19
LakePharma Enters into Licensing Agreement with XOMA 20
Torch Biosciences Enters into Licensing Agreement with XOMA 21
PRLA Pharma Enters into Licensing Agreement with XOMA 22
Novartis Enters into Licensing Agreement with XOMA for Gevokizumab 23
Novartis Enters into Licensing Agreement with XOMA 24
Xoma Plans To Enter Into Licensing Agreement For Perindopril 25
Xoma Enters into Licensing Agreement with Texas A&M University System 26
Symplmed Pharma Enters Into Licensing Agreement With Xoma For Perindopril Franchise 27
XOMA Enters into Licensing Agreement with Margaux Biologics for BPI 28
Equity Offering 29
XOMA Plans to Raise USD20 Million in Subscription Rights Offering 29
XOMA Files Registration Statement for Public Offering of Securities 30
Xoma Raises USD25 Million in Registered Direct Offering of Shares 31
Xoma Raises USD40 Million in Private Placement of Shares and Warrants 32
Xoma Completes Public Offering Of Shares For US$57.4 Million 34
Xoma Completes Public Offering Of Shares For US$31.6 Million 36
Xoma Completes Public Offering Of Shares For US$40 Million 37
XOMA Completes Public Offering Of Common Stock For US$39 Million 39
Asset Transactions 41
Agenus Acquires Antibody Manufacturing Facilities from XOMA 41
Nanotherapeutics Ammends agreement with XOMA 43
CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 44
XOMA Corp – Key Competitors 45
XOMA Corp – Key Employees 46
XOMA Corp – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Financial Announcements 48
Nov 07, 2018: XOMA reports third quarter 2018 financial results 48
Aug 07, 2018: XOMA reports second quarter 2018 financial results 49
May 09, 2018: XOMA Reports First Quarter 2018 Financial Results 50
Mar 07, 2018: XOMA Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update 51
Nov 06, 2017: XOMA Reports Third Quarter 2017 Financial Results 53
Aug 08, 2017: XOMA Reports Second Quarter 2017 Financial Results 54
May 09, 2017: XOMA Reports First Quarter 2017 Financial Results 55
Mar 16, 2017: XOMA Reports Fourth Quarter and Full Year 2016 Financial Results 56
Corporate Communications 58
Feb 16, 2017: XOMA Appoints Matthew Perry to its Board of Directors 58
Product News 59
03/23/2017: XOMA Provides Update On New Drug Candidate At The 2017 ENDO Meeting 59
Clinical Trials 60
Apr 18, 2017: XOMA Presents Positive Data from PTH1R Monoclonal Antibody Program 60
Mar 28, 2017: XOMA to Present Preclinical Data from its PTH1R Monoclonal Antibodies Program at the American Association for Cancer Research Annual Meeting 61
Other Significant Developments 62
Jun 26, 2018: XOMA Added to the Russell 2000 and Russell 3000 Indexes 62
Appendix 63
Methodology 63
About GlobalData 63
Contact Us 63
Disclaimer 63
XOMA Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XOMA Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XOMA Corp, Deals By Therapy Area, 2012 to YTD 2018 9
XOMA Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
XOMA Acquires Royalty Interest for Seven Assets from Agenus for USD15 Million 12
XOMA to Acquire Assets from Enumeral Biomedical for USD1.6 Million 13
XOMA Acquires US Rights To Perindopril Franchise From Les Laboratoires Servier 14
XOMA Sells Royalty Rights to HealthCare Royalty Partners 15
Domain Therapeutics Enters into Agreement with Xoma 16
Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 17
Rezolute Enters into Licensing Agreement with XOMA 18
Tizona Therapeutics Enters into Licensing Agreement with XOMA 19
LakePharma Enters into Licensing Agreement with XOMA 20
Torch Biosciences Enters into Licensing Agreement with XOMA 21
PRLA Pharma Enters into Licensing Agreement with XOMA 22
Novartis Enters into Licensing Agreement with XOMA for Gevokizumab 23
Novartis Enters into Licensing Agreement with XOMA 24
Xoma Plans To Enter Into Licensing Agreement For Perindopril 25
Xoma Enters into Licensing Agreement with Texas A&M University System 26
Symplmed Pharma Enters Into Licensing Agreement With Xoma For Perindopril Franchise 27
XOMA Enters into Licensing Agreement with Margaux Biologics for BPI 28
XOMA Plans to Raise USD20 Million in Subscription Rights Offering 29
XOMA Files Registration Statement for Public Offering of Securities 30
Xoma Raises USD25 Million in Registered Direct Offering of Shares 31
Xoma Raises USD40 Million in Private Placement of Shares and Warrants 32
Xoma Completes Public Offering Of Shares For US$57.4 Million 34
Xoma Completes Public Offering Of Shares For US$31.6 Million 36
Xoma Completes Public Offering Of Shares For US$40 Million 37
XOMA Completes Public Offering Of Common Stock For US$39 Million 39
Agenus Acquires Antibody Manufacturing Facilities from XOMA 41
Nanotherapeutics Ammends agreement with XOMA 43
CMC Biologics Acquires Manufacturing Operations And Affiliated Assets From Xoma 44
XOMA Corp, Key Competitors 45
XOMA Corp, Key Employees 46
XOMA Corp, Subsidiaries 47
List of Figures
XOMA Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
XOMA Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
XOMA Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9